The Oral Iron on the Prevention of Iron Deficiency Anemia in Obese Pregnant

Summary

Anemia is known as a condition in which the hemoglobin level is lower than normal. Anemia is one of the most common complications during pregnancy. Anemia in pregnancy is defined as a hemoglobin level \< 110 g/L . Anemia is an important risk factor in pregnancy which leads to both maternal and fetal morbidity and mortality.

The pregnant woman needs more iron during pregnancy, so iron deficiency anemia is very common during pregnancy. In Egypt; iron deficiency anemia affects about one in every two pregnant women, especially in rural areas. Pregnant women require about 27 mg/day elemental iron to cover their increased need. The pregnant women should start taking a daily supplement of 30mg of elemental iron as a preventive measure against iron deficiency anemia especially in poor countries.

Obesity is defined as having an excessive amount of body fat. The body mass index, a measurement based on height and weight, determines the obese if the figure more than 30 kg/m2. There is an increased rate of overweight and obesity among pregnant women. According to the World Health Organization, 46% of adult females in Egypt are obese.

Many researches in the literature revealed a strong relationship between high BMI in pregnancy and iron deficiency anemia. Hepcidin is an iron regulating hormone in the body. Increases in iron levels in the plasma stimulate the production of hepcidin, which blocks iron absorption from the diet, so; hepcidin production is suppressed in the case of iron deficiency.

Conditions

• Anemia of Pregnancy

Interventions

DRUG

Iron

PharaFerro27; Devart Lab Company, Egypt

DIAGNOSTIC_TEST

Complete blood count

to assess the anemia

DIAGNOSTIC_TEST

Serum ferritin

to assess the anemia

DIAGNOSTIC_TEST

Serum hepcidin

to assess the iron abosrption

DIAGNOSTIC_TEST

Serum Iron

to assess the anemia

DIAGNOSTIC_TEST

Serum total iron binding capacity

to assess the anemia

Sponsors & Collaborators

• Assiut University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

35 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-10-01

Primary Completion

2022-04-01

Completion

2022-04-01

Countries

• Egypt

Study Locations